Shots: Wugen to get exclusive & IPR rights for CAR-T Technologies developed by Washington University The focus of the agreement is to develop and commercialize novel CAR-T therapies to treat blood cancer The novel CAR-T therapy platform including fratricide-resistant “off-the-shelf” system, targeting CD7+ T cell malignancies Click here to read full press release/ article | […]Read More
Tags : CAR-T Therapy Technologies
Latest Posts
Categories
Related Topics
AbbVie
Acquire
Adults
Agreement
Amgen
approval
AstraZeneca
Bayer
Biosimilar
BMS
Collaborate
Collaborates
Collaboration
Commercialize
COVID-19
Develop
Development
Eli Lilly
EU
Exclusive
FDA
Gilead
GSK
Janssen
Launches
License
License Agreement
Merck
Novartis
P-III
patients
Pfizer
receives
Report
reports
results
Roche
Sanofi
Signs
study
Takeda
the US FDA
Treat
Treatment
US